Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Syndax Pharmaceuticals initiated with a Outperform at FBR & Co.; tgt $27 (14.72)FBR & Co. initiates SNDX with a Outperform and price target of $27. Syndax is a biotechnology company that has received breakthrough designation from the FDA for its lead product candidate, entinostat, which is in Phase III development for the treatment of hormone receptor positive (HR+) breast cancer. Syndax also has several immuno-oncology collaborations with major pharma/biotech companies for the development of combination therapy with their checkpoint inhibitors plus entinostat for other cancer indications. In addition, Syndax is developing a next-generation tumor microenvironment modulating agent (SNDX-6352) that could potentially have a broad indication in cancer therapy. <strong>The company is capitalized into mid 2018, and firm believes there are several catalysts in 2017 that could move the stock higher.</strong></td> </tr></table>"